Search research articles
Contact Us
Filters
Showing results (111-120 of 268) with videos related to
Page
of 27
Sort By:
Lung Cancer (Amsterdam, Netherlands)
|
December 19, 2016
The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials
Bob T Li, Tristan A Barnes, David L Chan, et al.
Cancer Genetics
|
December 20, 2021
Diagnostic testing approaches for the identification of patients with TRK fusion cancer prior to enrollment in clinical trials investigating larotrectinib
Erin R Rudzinski, Jaclyn Hechtman, Sinchita Roy-Chowdhuri, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 11, 2021
Invasive Mucinous Adenocarcinomas With Spatially Separate Lung Lesions: Analysis of Clonal Relationship by Comparative Molecular Profiling
Soo-Ryum Yang, Jason C Chang, Charles Leduc, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 12, 2012
Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions
Yoshiyuki Suehara, Maria Arcila, Lu Wang, et al.
The Journal of Molecular Diagnostics : JMD
|
April 17, 2022
Clinical Utility and Performance of an Ultrarapid Multiplex RNA-Based Assay for Detection of ALK, ROS1, RET, and NTRK1/2/3 Rearrangements and MET Exon 14 Skipping Alterations
Ying-Hsia Chu, Jada Barbee, Soo-Ryum Yang, et al.
JCO Precision Oncology
|
April 23, 2025
Larotrectinib Compared With Real-World Non-Tropomyosin Receptor Kinase Inhibitor Therapies in Patients With Tropomyosin Receptor Kinase Fusion Cancer
Marcia S Brose, C Benedikt Westphalen, Xiaoyun Pan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 4, 2020
A Performance Comparison of Commonly Used Assays to Detect RET Fusions
Soo-Ryum Yang, Umut Aypar, Ezra Y Rosen, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
August 4, 2019
NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls
James P Solomon, Irina Linkov, Andrea Rosado, et al.
Communications Biology
|
December 17, 2020
NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors
Romel Somwar, Nicolle E Hofmann, Bryan Smith, et al.
Cancers
|
March 13, 2025
Population-Adjusted Indirect Treatment Comparisons of Repotrectinib Among Patients with <i>ROS1+</i> NSCLC
Jürgen Wolf, Sarah Goring, Adam Lee, et al.
Page
of 27
Search research articles
Search
Showing results (111-120 of 268) with videos related to
Sort By:
Page
of 27
Lung Cancer (Amsterdam, Netherlands)
|
December 19, 2016
The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials
Bob T Li, Tristan A Barnes, David L Chan, et al.
Cancer Genetics
|
December 20, 2021
Diagnostic testing approaches for the identification of patients with TRK fusion cancer prior to enrollment in clinical trials investigating larotrectinib
Erin R Rudzinski, Jaclyn Hechtman, Sinchita Roy-Chowdhuri, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 11, 2021
Invasive Mucinous Adenocarcinomas With Spatially Separate Lung Lesions: Analysis of Clonal Relationship by Comparative Molecular Profiling
Soo-Ryum Yang, Jason C Chang, Charles Leduc, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 12, 2012
Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions
Yoshiyuki Suehara, Maria Arcila, Lu Wang, et al.
The Journal of Molecular Diagnostics : JMD
|
April 17, 2022
Clinical Utility and Performance of an Ultrarapid Multiplex RNA-Based Assay for Detection of ALK, ROS1, RET, and NTRK1/2/3 Rearrangements and MET Exon 14 Skipping Alterations
Ying-Hsia Chu, Jada Barbee, Soo-Ryum Yang, et al.
JCO Precision Oncology
|
April 23, 2025
Larotrectinib Compared With Real-World Non-Tropomyosin Receptor Kinase Inhibitor Therapies in Patients With Tropomyosin Receptor Kinase Fusion Cancer
Marcia S Brose, C Benedikt Westphalen, Xiaoyun Pan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 4, 2020
A Performance Comparison of Commonly Used Assays to Detect RET Fusions
Soo-Ryum Yang, Umut Aypar, Ezra Y Rosen, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
August 4, 2019
NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls
James P Solomon, Irina Linkov, Andrea Rosado, et al.
Communications Biology
|
December 17, 2020
NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors
Romel Somwar, Nicolle E Hofmann, Bryan Smith, et al.
Cancers
|
March 13, 2025
Population-Adjusted Indirect Treatment Comparisons of Repotrectinib Among Patients with <i>ROS1+</i> NSCLC
Jürgen Wolf, Sarah Goring, Adam Lee, et al.
Page
of 27